Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward B Garon

Showing results (11-20 of 204) with videos related to

Pageof 21
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Proapoptotic agents in lung cancerPeter Ujhazy, Edward B Garon
JAMA Oncology|March 18, 2016
The Value of PD-L1 Testing in Non-Small-Cell Lung CancerAaron Lisberg, Edward B Garon
Drugs|February 27, 2021
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung CancerEdward B Garon, Paige Brodrick
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 31, 2018
The Italian Nivolumab Expanded Access Program Confirms the Limitations of Single-Agent PD-1 Inhibition in EGFR-Mutant and Never-Smoking Patients with NSCLCAaron Lisberg, Edward B Garon
Oncology (Williston Park, N.Y.)|December 16, 2010
Management of small-cell lung cancer: time to move forwardJuliet Pollock, Edward B Garon
Translational Lung Cancer Research|January 5, 2018
Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational studyAaron Lisberg, Edward B Garon
Translational Lung Cancer Research|May 21, 2019
Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancerAaron Lisberg, Edward B Garon
Cancer Biology & Medicine|January 27, 2018
The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?Amy L Cummings, Edward B Garon
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 20, 2012
Targeting MEK for the treatment of non-small-cell lung cancerJonathan W Goldman, Edward B Garon
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Poly(ADP-ribose) polymerase inhibitorsEdward B Garon, Steven M Dubinett
Pageof 21

Showing results (11-20 of 204) with videos related to

Sort By:
Pageof 21
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Proapoptotic agents in lung cancerPeter Ujhazy, Edward B Garon
JAMA Oncology|March 18, 2016
The Value of PD-L1 Testing in Non-Small-Cell Lung CancerAaron Lisberg, Edward B Garon
Drugs|February 27, 2021
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung CancerEdward B Garon, Paige Brodrick
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 31, 2018
The Italian Nivolumab Expanded Access Program Confirms the Limitations of Single-Agent PD-1 Inhibition in EGFR-Mutant and Never-Smoking Patients with NSCLCAaron Lisberg, Edward B Garon
Oncology (Williston Park, N.Y.)|December 16, 2010
Management of small-cell lung cancer: time to move forwardJuliet Pollock, Edward B Garon
Translational Lung Cancer Research|January 5, 2018
Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational studyAaron Lisberg, Edward B Garon
Translational Lung Cancer Research|May 21, 2019
Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancerAaron Lisberg, Edward B Garon
Cancer Biology & Medicine|January 27, 2018
The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?Amy L Cummings, Edward B Garon
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 20, 2012
Targeting MEK for the treatment of non-small-cell lung cancerJonathan W Goldman, Edward B Garon
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Poly(ADP-ribose) polymerase inhibitorsEdward B Garon, Steven M Dubinett
Pageof 21